Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Paul Milne"'
Autor:
Michelangelo Tesi, Francesco Pegoraro, Francesco Peyronel, Martina Mazzariol, Elena Gelain, Matthew Koster, Ronald Go, Gaurav Goyal, Matthew Collin, Paul Milne, Sarah Pagan, Fleur Cohen-Aubart, Matthias Papo, Juvianee Estrada-Veras, Roei Mazor, Lorenzo Dagna, Eli Diamond, Augusto Vaglio, Julien Haroche
Publikováno v:
HemaSphere, Vol 7, p e4740525 (2023)
Externí odkaz:
https://doaj.org/article/aa24d3378ee74adbae97370685f854c2
Autor:
Paul Milne, Helen J. Blair, Cornelia Eckert, Zoya Kingsbury, Matthew Collin, Anetta Ptasinska, Alex Elder, Roderick Skinner, Janine Stutterheim, Jennifer Becq, Elena Zerkalenkova, Constanze Bonifer, Denis M. Schewe, Peter N. Cockerill, N Martinez-Soria, Oskar A. Haas, Peter Carey, Katarzyna Szoltysek, Deepali Pal, Hesta McNeill, Claus Meyer, Maria Rosaria Imperato, James C. Mulloy, Mark Wunderlich, Catherine Cargo, Paul Evans, Sarah E. Fordham, Shan Lin, Pierre Cauchy, Y Shi, Simon Bailey, Salam A. Assi, Rolf Marschalek, Josef Vormoor, Olaf Heidenreich, A Komkov, Michael J. Thirman, Simon Bomken, Ricky Tirtakusuma, Sirintra Nakjang, Fotini Vogiatzi, James M. Allan, Lisa J. Russell, Jayne Y. Hehir-Kwa, Muzlifah Haniffa, Yulia Olshanskaya, Vasily V. Grinev, Christine J. Harrison, Venetia Bigley, Daniel Williamson, Alex Smith, Natalia Miakova
Publikováno v:
Blood. 140:1875-1890
The fusion gene MLL-AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukaemia. However, relapse can be associated with a switch from acute lymphoblastic to acute myeloid leukaemia. Here we show that these myeloid relapses share oncogene
Autor:
Paul Milne, Harshal Abhyankar, Brooks Scull, Preeti Singh, Rikhia Chakraborty, Carl E. Allen, Matthew Collin
Publikováno v:
Blood Advances. 6:4901-4904
Autor:
Imogen G. Franklin, Paul Milne, Jordan Childs, Róisín M. Boggan, Isabel Barrow, Conor Lawless, Gráinne S Gorman, Yi Shiau Ng, Matthew Collin, Oliver M. Russell, Sarah J. Pickett
Pathogenic mitochondrial (mt)DNA single nucleotide variants are the most common cause of adult mitochondrial disease. Whilst levels of the most common heteroplasmic variant (m.3243A>G) remain stable in post-mitotic tissues, levels in mitotic tissues,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e3712599f8f2d049f42660066a6823
https://doi.org/10.1101/2023.04.26.23289145
https://doi.org/10.1101/2023.04.26.23289145
Autor:
Egle Kvedaraite, Paul Milne, Ahad Khalilnezhad, Marion Chevrier, Raman Sethi, Hong Kai Lee, Daniel W. Hagey, Tatiana von Bahr Greenwood, Natalia Mouratidou, Martin Jädersten, Nicole Yee Shin Lee, Lara Minnerup, Yingrou Tan, Charles-Antoine Dutertre, Nathan Benac, You Yi Hwang, Josephine Lum, Amos Hong Pheng Loh, Jessica Jansson, Karen Wei Weng Teng, Shabnam Khalilnezhad, Weili Xu, Anastasia Resteu, Hong Liang Tey, Ng Lai Guan, Anis Larbi, Shanshan Wu Howland, Henrik Arnell, Samir E. L. Andaloussi, Jorge Braier, Georgios Rassidakis, Laura Galluzzo, Andrzej Dzionek, Jan-Inge Henter, Jinmiao Chen, Matthew Collin, Florent Ginhoux
Publikováno v:
Science Immunology. 7
Langerhans cell histiocytosis (LCH) is a potentially fatal neoplasm characterized by the aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein kinase (MAPK) pathway activation. LCH cells may trigger destructive patho
Autor:
Paul Milne, Simon Bomken, Olga Slater, Ashish Kumar, Adam Nelson, Somak Roy, Jessica Velazquez, Kshitij Mankad, James Nicholson, Dan Yeomanson, Richard Grundy, Ahmed Kamal, Anthony Penn, Jane Pears, Gerard Millen, Bruce Morland, James Hayden, Jason Lam, Maymoon Madkhali, Jamie MacDonald, Preeti Singh, Sarah Pagan, Carlos Rodriguez-Galindo, Milen Minkov, Jean Donadieu, Jennifer Picarsic, Carl Allen, Venetia Bigley, Matthew Collin
Publikováno v:
Blood advances.
Most children with high-risk Langerhans cell histiocytosis (LCH) have BRAFV600E mutation. BRAFV600E alleles are detectable in myeloid mononuclear cells at diagnosis but it is not known if the cellular distribution of mutation evolves over time. Here,
Autor:
Mrinal M. Patnaik, Paul Milne, Daniel H. Wiseman, Naveen Pemmaraju, Deepti P. Wilks, Hasse M Bossenbroek, Kiran Batta, Hannah C. Beird, Tim C. P. Somervaille, Michael Dennis, Justin Taylor, Catherine Cargo, Richard Chasty, Matthew Collin
Publikováno v:
Leukemia
Autor:
Michael Poidinger, Howard Lin, Kaibo Duan, Miriam Merad, Kenneth L. McClain, Naomi McGovern, Daniel J. Zinn, Evan W. Newell, Brooks Scull, Carl E. Allen, Rikhia Chakraborty, Florent Ginhoux, Karen Phaik Har Lim, Tsz-Kwong Man, Olive S. Eckstein, Thomas M. Burke, Matthew Collin, Harshal Abhyankar, Amel Sengal, Paul Milne
Publikováno v:
Blood Advances. 4:87-99
Langerhans cell histiocytosis (LCH) is a myeloproliferative disorder that is characterized by the inflammatory lesions with pathogenic CD1a(+)CD207(+) dendritic cells (DCs). BRAFV600E and other somatic activating MAPK gene mutations have been identif
Autor:
Johannes Visser, Anne Lutun, Elena Sieni, Fleur Cohen, Nabil Kabbara, Olga Slater, Jean-François Emile, Mathilde Jehanne, Alina Ferster, Michael Maschan, Houda Boudiaf, Pascale Schneider, Sarah Elitzur, Nathalie Aladjidi, Milen Minkov, Ahmed Idbaih, Matthew Collin, Michal Golan, Alexandra Kolenova, François Chalard, Karel Svojgr, Jean Donadieu, Anne Pagnier, Laurence Blanc, Nicolas Simon, Jean-Claude Alvarez, Islam Amine Larabi, Fanette Bernard, James Nicholson, Mohamed Barkaoui, Anne Sonntagbauer, Anne Lambilliote, Thomas Lehrnbecher, Dmitriy Evseev, Viktoria Efremova, Geneviève Plat, Martina Ahlmann, Jean Miron, Valérie Taly, Caroline Hutter, Julien Haroche, Zofia Hélias-Rodzewicz, Paul Milne, Sébastien Héritier, Andrej Lissat, Mathilde Tardieu
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, In press, pp.JCO.19.00456. ⟨10.1200/JCO.19.00456⟩
Journal of Clinical Oncology, In press, pp.JCO.19.00456. ⟨10.1200/JCO.19.00456⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, In press, pp.JCO.19.00456. ⟨10.1200/JCO.19.00456⟩
Journal of Clinical Oncology, In press, pp.JCO.19.00456. ⟨10.1200/JCO.19.00456⟩
PURPOSE Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation–positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were clas
Publikováno v:
Therapeutic Innovation & Regulatory Science. 53:609-614
Surveys evaluating industry experience with performing pediatric studies under the Best Pharmaceutical for Children Act (BPCA) and Pediatric Research Equity Act (PREA) regulatory regime were conducted by Tufts Center for the Study of Drug Development